Breast Surgery — MCQs

Breast Surgery Indian Medical PG Practice Questions and MCQs

Question 81: Which of the following is NOT related to Mondor's disease?

A. Lymphedema of upper limb
B. Risk factor for breast cancer
C. Variant of thrombophlebitis (Correct Answer)
D. Mastectomy is the treatment of choice

Explanation: **Explanation:** **Mondor’s Disease** is a rare, benign condition characterized by **superficial thrombophlebitis** of the subcutaneous veins of the breast and anterior chest wall. It most commonly involves the lateral thoracic, thoracoepigastric, or superior epigastric veins. 1. **Why Option C is the Correct Answer:** The question asks which is **NOT** related to Mondor's disease. However, based on standard medical definitions, Mondor's disease **is** a variant of thrombophlebitis. *Note: If the question asks for the "NOT" related option, there may be a typographical error in the provided key, as A, B, and D are all incorrect statements, while C is a true clinical fact about the disease.* 2. **Analysis of Other Options:** * **Option A (Lymphedema):** Mondor’s disease does not cause lymphedema. It is a venous pathology, not a lymphatic one. * **Option B (Risk factor for cancer):** Mondor’s disease is **not** a risk factor for breast cancer. It is a self-limiting, benign condition, though it can occasionally be associated with underlying malignancy in rare cases. * **Option D (Mastectomy):** Mastectomy is never indicated. The treatment is **conservative**, involving reassurance, warm compresses, and NSAIDs for pain relief. **Clinical Pearls for NEET-PG:** * **Clinical Presentation:** Patients present with a sudden onset of a **painful, palpable "cord-like" structure** on the breast or chest wall. * **Skin Changes:** "Groove sign" or skin tethering may be seen when the arm is elevated. * **Etiology:** Often idiopathic but can follow trauma, vigorous exercise, or breast surgery. * **Management:** It is self-limiting and usually resolves spontaneously within 4 to 8 weeks. No anticoagulation is required.

Question 82: Breast conservation surgery is contraindicated in which of the following conditions?

A. Tumor size > 4 cm
B. Multicentric tumor
C. Axillary lymph node involvement
D. All of the above (Correct Answer)

Explanation: **Explanation:** Breast Conservation Surgery (BCS) aims to remove the tumor with a clear margin while maintaining cosmetic integrity. The primary goal is to achieve local control equivalent to a mastectomy. **Why "All of the Above" is Correct:** The contraindications for BCS are categorized into absolute and relative. The options provided represent scenarios where BCS is either technically unfeasible or oncologically unsafe: 1. **Multicentric Tumor (Absolute Contraindication):** Multicentricity refers to tumors in different quadrants of the breast. Attempting BCS in this scenario would require multiple incisions or a large volume of tissue removal, leading to poor cosmesis and a high risk of local recurrence. 2. **Tumor Size > 4 cm (Relative Contraindication):** While the tumor-to-breast ratio is the actual deciding factor, a tumor >4 cm (T3) generally makes it difficult to achieve negative margins without significant deformity. Large tumors often require Neoadjuvant Chemotherapy (NACT) to downstage them before BCS can be considered. 3. **Axillary Lymph Node Involvement:** While not an absolute contraindication in modern practice, extensive nodal involvement often correlates with advanced disease where mastectomy may be preferred to ensure regional control, especially if inflammatory components are present. **High-Yield Clinical Pearls for NEET-PG:** * **Absolute Contraindications to BCS:** * Prior radiation therapy to the breast/chest wall. * Pregnancy (Radiotherapy is required post-BCS and is contraindicated in pregnancy). * Diffuse suspicious microcalcifications on mammography. * Widespread multicentric disease. * Persistent positive margins after re-excision. * **Relative Contraindications:** Active connective tissue diseases (e.g., Scleroderma, SLE) due to poor tolerance of radiotherapy. * **Standard Protocol:** BCS must *always* be followed by **Adjuvant Radiotherapy** to reduce the risk of local recurrence. If a patient cannot undergo radiation, they must undergo a mastectomy.

Question 83: A 30-year-old female presents with complaints of cord-like structures on her arm and breast, with no history of injury or infection. These cords are best demonstrated on elevation of the hand. What is the most possible diagnosis?

A. Poland syndrome
B. Teitz disease
C. Mondor's disease (Correct Answer)
D. Duct ectasia

Explanation: **Explanation:** The clinical presentation of palpable, cord-like structures on the breast and arm that become more prominent upon limb elevation is pathognomonic for **Mondor’s Disease**. **1. Why Mondor’s Disease is Correct:** Mondor’s disease is a **superficial thrombophlebitis** affecting the veins of the breast and anterior chest wall (most commonly the lateral thoracic, thoracoepigastric, or superior epigastric veins). The "cord-like" feel represents the thrombosed vein. Elevating the arm stretches the skin over the vein, making the cord more visible—a classic clinical sign. It is usually self-limiting and managed with NSAIDs. **2. Why Other Options are Incorrect:** * **Poland Syndrome:** A congenital anomaly characterized by the unilateral absence of the pectoralis major muscle, often associated with syndactyly. It does not present with cord-like structures. * **Tietze Disease:** An inflammatory condition causing painful swelling of the costochondral junctions (rib cartilage). It presents as localized chest wall pain/swelling, not superficial venous cords. * **Duct Ectasia:** A benign condition involving dilation of the lactiferous ducts, typically presenting with nipple discharge (green/brown) and subareolar masses, not superficial chest wall findings. **3. NEET-PG High-Yield Pearls:** * **Triad of Veins:** Lateral thoracic, Thoracoepigastric, and Superior epigastric veins. * **Clinical Sign:** The "Iron Wire" or "Bowstring" sign (prominence on abduction/elevation of the arm). * **Etiology:** Often idiopathic, but can follow vigorous exercise, breast surgery, or trauma. * **Association:** While usually benign, in rare cases, it can be a marker for underlying breast malignancy; hence, a mammogram is often recommended in older patients.

Question 84: A female patient presented with a firm mass of 2 x 2 cm in the upper outer quadrant of the breast. She gives a family history of ovarian carcinoma. What investigation needs to be done to assess for mutation?

A. p53
B. BRCA-2 (Correct Answer)
C. Her 2/Neu gene
D. C-myc gene

Explanation: ### Explanation **Correct Answer: B. BRCA-2** The clinical presentation of a breast mass in a patient with a strong family history of ovarian carcinoma strongly suggests **Hereditary Breast and Ovarian Cancer (HBOC) syndrome**. 1. **Why BRCA-2 is correct:** Mutations in the **BRCA1** and **BRCA2** genes are the most common causes of hereditary breast cancer. While both are associated with ovarian cancer, **BRCA2** is specifically linked to a higher risk of male breast cancer and is frequently tested when there is a dual history of breast and ovarian malignancies in a family. In the context of this question, it is the most relevant gene to assess for a germline mutation. **Analysis of Incorrect Options:** * **A. p53:** Mutations in the *TP53* gene are associated with **Li-Fraumeni Syndrome**. While this syndrome increases the risk of breast cancer, it is typically characterized by a broad spectrum of tumors, including sarcomas, brain tumors, and adrenocortical carcinomas, rather than a specific link to ovarian cancer. * **C. Her 2/Neu:** This is a proto-oncogene used as a **prognostic and predictive biomarker** in biopsy samples to guide treatment (e.g., Trastuzumab). It is an acquired somatic mutation, not a germline mutation used to assess familial risk. * **D. C-myc:** This is an oncogene often overexpressed in various cancers (like Burkitt lymphoma), but it is not a standard screening target for hereditary breast-ovarian cancer syndromes. **High-Yield Clinical Pearls for NEET-PG:** * **BRCA1:** Located on **Chromosome 17**. Associated with Triple Negative Breast Cancer (TNBC) and a higher lifetime risk of ovarian cancer (up to 40%). * **BRCA2:** Located on **Chromosome 13**. Associated with Luminal-type breast cancers and is the most common gene implicated in **Male Breast Cancer**. * **HBOC Screening:** Indicated if there are multiple family members with breast/ovarian cancer, bilateral breast cancer, or young age of onset (<50 years).

Question 85: Which of the following conditions is NOT related to Aberrations of Normal Development and Involution (ANDI) of the breast?

A. Fibroadenoma
B. Duct ectasia
C. Cyclical mastalgia
D. Intraductal papilloma (Correct Answer)

Explanation: **Explanation:** The concept of **ANDI (Aberrations of Normal Development and Involution)**, proposed by Hughes and Mansel, classifies benign breast disorders based on the normal physiological processes of the breast: development, cyclical change, and involution. It distinguishes between normal variations, minor aberrations, and true disease. **Why Intraductal Papilloma is the correct answer:** Intraductal papilloma is considered a **true neoplastic process** (a discrete benign tumor of the lactiferous ducts) rather than a deviation from normal physiological development or involution. Therefore, it does not fall under the ANDI classification. **Analysis of Incorrect Options:** * **Fibroadenoma (Option A):** This is an aberration of the **Development** phase (ages 15–25). It arises from the overgrowth of a single lobule. Giant fibroadenomas are considered "disease," while standard ones are "aberrations." * **Duct Ectasia (Option B):** This is an aberration of **Involution** (specifically stromal and ductal involution). It occurs when the subareolar ducts dilate and fill with debris, typically in the 50s. * **Cyclical Mastalgia (Option C):** This is an aberration of **Cyclical Changes** during the reproductive years. While mild tenderness is normal, severe cyclical pain is classified as an ANDI aberration. **NEET-PG High-Yield Pearls:** * **ANDI Categories:** 1. **Development (15–25 yrs):** Fibroadenoma, Adolescent hypertrophy. 2. **Cyclical Changes (Period of activity):** Cyclical mastalgia, Nodularity. 3. **Involution (35–55 yrs):** Cysts, Sclerosing adenosis, Duct ectasia, Periductal fibrosis. * **Clinical Note:** Intraductal papilloma is the most common cause of **bloody nipple discharge** from a single duct. * **Management:** Most ANDI conditions are managed conservatively once malignancy is ruled out (Triple Assessment).

Question 86: Breast conservative surgery is indicated in all of the following conditions except:

A. Young patients
B. Ductal carcinoma in situ
C. Lobular carcinoma (Correct Answer)
D. Infiltrative ductal carcinoma

Explanation: **Explanation:** Breast Conservative Surgery (BCS) aims to remove the tumor with a clear margin while preserving the breast. The choice between BCS and Mastectomy depends on the tumor's ability to be completely excised with good cosmetic results and a low risk of local recurrence. **Why Lobular Carcinoma (ILC) is the correct answer:** Invasive Lobular Carcinoma (ILC) is traditionally considered a relative contraindication or a challenging case for BCS. This is because ILC is characterized by a **"diffuse, infiltrative growth pattern"** (single-file cells) and lacks a cohesive mass. It is frequently **multifocal** (multiple foci in the same quadrant) and **multicentric** (different quadrants), making it difficult to achieve negative surgical margins. While modern guidelines allow BCS for ILC if margins are clear, in the context of standard surgical teaching and competitive exams, its multicentric nature makes it the "except" choice compared to localized ductal lesions. **Analysis of Incorrect Options:** * **Young Patients:** Age is not a contraindication for BCS. While younger patients may have a slightly higher local recurrence rate, BCS followed by radiotherapy is the standard of care. * **Ductal Carcinoma in Situ (DCIS):** BCS (lumpectomy) followed by radiation is a standard treatment for localized DCIS. * **Infiltrative Ductal Carcinoma (IDC):** IDC usually forms a solid, cohesive lump, making it the most common and ideal indication for BCS, provided the tumor-to-breast size ratio is favorable. **Clinical Pearls for NEET-PG:** * **Absolute Contraindications for BCS:** Multicentric disease, pregnancy (radiotherapy is contraindicated), prior radiation to the chest wall, and persistent positive margins after re-excision. * **BCS Components:** Lumpectomy + Axillary staging (SLNB/ALND) + Whole Breast Irradiation. * **Tumor Size:** Generally, tumors <4 cm are ideal for BCS; larger tumors may require Neoadjuvant Chemotherapy (NACT) to downstage them before BCS.

Question 87: What condition is characterized by greenish-black discharge from the breast?

A. Duct ectasia (Correct Answer)
B. Intraductal papilloma
C. Carcinoma of the breast
D. Paget disease of the nipple

Explanation: **Explanation:** **Duct Ectasia** is the correct answer because it is a chronic inflammatory condition characterized by the dilation of subareolar ducts. As the ducts dilate, they become filled with stagnant lipid-rich secretions and cellular debris. Over time, these secretions thicken and undergo chemical changes, resulting in a characteristic **multiductal, thick, "toothpaste-like" or greenish-black (creamy) nipple discharge**. It is most commonly seen in perimenopausal women and is often associated with smoking. **Why the other options are incorrect:** * **Intraductal Papilloma:** This is the most common cause of **bloody (serosanguinous)** nipple discharge. It is typically a spontaneous, single-duct discharge. * **Carcinoma of the Breast:** While breast cancer can cause discharge (usually bloody or serous), it is more frequently associated with a painless, hard lump, skin tethering, or nipple retraction. * **Paget Disease of the Nipple:** This presents as an **eczematous-like lesion** of the nipple-areola complex (itching, redness, crusting). It is an intraepithelial manifestation of an underlying ductal carcinoma. **High-Yield Clinical Pearls for NEET-PG:** * **Duct Ectasia** can lead to "Plasma Cell Mastitis" due to the inflammatory response to leaked secretions. * **Clinical Presentation:** It may present with a slit-like nipple retraction (transverse) and a subareolar mass that mimics malignancy. * **Management:** If troublesome, the definitive treatment is a **Hadfield’s operation** (total excision of the major duct system). * **Mnemonic for Discharge:** Green/Black = Ectasia; Bloody = Papilloma; Milky = Galactorrhea (Prolactinoma).

Question 88: A 45-year-old female patient with a family history of breast carcinoma presented with diffuse microcalcification on mammography. Biopsy revealed intraductal carcinoma in situ. What is the most appropriate management?

A. Quadrantectomy
B. Radical mastectomy
C. Simple mastectomy (Correct Answer)
D. Chemotherapy

Explanation: ### Explanation The correct management for this patient is **Simple Mastectomy**. **1. Why Simple Mastectomy is the correct answer:** Ductal Carcinoma In Situ (DCIS) is a pre-invasive malignancy. While Breast Conserving Surgery (BCS) like quadrantectomy is often preferred for localized DCIS, this patient presents with **diffuse microcalcifications**. Diffuse or multicentric disease is a primary contraindication for BCS because it is impossible to achieve clear surgical margins while maintaining an acceptable cosmetic result. In such cases, a **Simple (Total) Mastectomy**—which removes the entire breast tissue including the nipple-areolar complex but spares the axillary lymph nodes—is the standard of care. **2. Why the other options are incorrect:** * **Quadrantectomy (BCS):** Incorrect because the microcalcifications are **diffuse**. BCS requires localized disease where negative margins can be obtained. * **Radical Mastectomy:** Incorrect and obsolete. This procedure (Halsted) removes the breast, pectoralis muscles, and all axillary nodes. It is not indicated for DCIS, which is non-invasive. * **Chemotherapy:** Incorrect. DCIS is a localized, non-invasive condition. Systemic chemotherapy is reserved for invasive carcinomas. Hormonal therapy (Tamoxifen) may be used as an adjuvant to reduce recurrence, but it is not the primary treatment. **3. NEET-PG High-Yield Pearls:** * **DCIS Hallmark:** Microcalcifications on mammography (typically pleomorphic or "crushed stone" appearance). * **Comedo type DCIS:** The most aggressive subtype with a high risk of progression to invasive cancer. * **Axillary Management:** Since DCIS is non-invasive, routine Axillary Lymph Node Dissection (ALND) is **not** required. However, if a mastectomy is performed for DCIS, a **Sentinel Lymph Node Biopsy (SLNB)** is often done simultaneously because an invasive component might be discovered on final pathology. * **Van Nuys Prognostic Index:** Used to determine the risk of local recurrence and guide the choice between BCS and mastectomy.

Question 89: What is the most common quadrant for breast carcinoma?

A. Lower outer
B. Lower inner
C. Upper outer (Correct Answer)
D. Upper inner

Explanation: **Explanation:** The distribution of breast carcinoma is directly proportional to the amount of glandular tissue present in each quadrant. The **Upper Outer Quadrant (UOQ)** contains the largest volume of breast parenchyma (glandular tissue) and extends into the axilla as the **Axillary Tail of Spence**. Consequently, approximately **50% to 60%** of all breast cancers originate in this quadrant, making it the most common site. **Analysis of Options:** * **A. Lower Outer (LOQ):** This quadrant contains significantly less glandular tissue than the upper half. It accounts for approximately 10% of breast cancers. * **B. Lower Inner (LIQ):** This is the least common site for breast carcinoma, accounting for roughly 5% of cases. * **D. Upper Inner (UIQ):** While more common than the lower quadrants (accounting for about 15%), it lacks the density and the additional "tail" of tissue found in the UOQ. **NEET-PG High-Yield Pearls:** 1. **Order of Frequency:** UOQ (50%) > Central/Subareolar (20%) > UIQ (15%) > LOQ (10%) > LIQ (5%). 2. **Axillary Tail of Spence:** This is a normal extension of the UOQ that pierces the deep fascia (Foramen of Langer) to enter the axilla. Tumors here can sometimes be mistaken for axillary lymphadenopathy. 3. **Multicentricity:** Breast cancer is often multicentric (multiple tumors in different quadrants), which is a key consideration when deciding between Breast Conserving Surgery (BCS) and Mastectomy. 4. **Clinical Presentation:** The most common presentation is a **painless, hard, fixed lump**. The UOQ is also the most common site for benign lesions like fibroadenomas.

Question 90: A 27-year-old woman requests a mammogram due to a strong family history of early-onset breast cancer. Which of the following factors would significantly increase this patient's risk for breast cancer?

A. Multiparity
B. High-fiber diet
C. Oral contraceptive use
D. BRCA1 mutation (Correct Answer)

Explanation: **Explanation:** **1. Why BRCA1 mutation is correct:** The **BRCA1 mutation** is a high-penetrance germline mutation that significantly increases the lifetime risk of breast cancer (up to 60-80%) and ovarian cancer (up to 40%). In a young patient (27 years old) with a strong family history, genetic predisposition is the most significant risk factor. BRCA1-associated breast cancers are often "triple-negative" and occur at an earlier age compared to the general population. **2. Why the other options are incorrect:** * **Multiparity (A):** This is actually a **protective factor**. Early first full-term pregnancy and having multiple children reduce the total number of ovulatory cycles and promote terminal differentiation of breast epithelium, lowering risk. * **High-fiber diet (B):** This is generally considered a **protective or neutral factor**. Diets high in fiber and low in fat are associated with lower circulating estrogen levels, potentially reducing risk. * **Oral contraceptive use (C):** While some studies suggest a very slight, transient increase in risk during active use, it is **not as significant** as a genetic mutation. Furthermore, OCPs are known to significantly *decrease* the risk of ovarian and endometrial cancers. **Clinical Pearls for NEET-PG:** * **Screening in High Risk:** For BRCA carriers, screening starts early (age 25) with **Annual MRI**, as mammography is less sensitive in the dense breast tissue of young women. * **BRCA1 vs. BRCA2:** BRCA1 is on Chromosome **17q** (associated with Triple Negative Breast Cancer); BRCA2 is on Chromosome **13q** (associated with Male Breast Cancer). * **Gail Model:** The most commonly used tool to estimate the 5-year and lifetime risk of invasive breast cancer. * **Li-Fraumeni Syndrome:** Another high-yield genetic cause involving the **p53 mutation**, leading to early-onset breast cancer and sarcomas.

Practice by Chapter

Breast Anatomy and Physiology

Practice Questions

Benign Breast Diseases

Practice Questions

Breast Cancer Screening

Practice Questions

Breast Cancer: Diagnosis and Staging

Practice Questions

Surgical Management of Breast Cancer

Practice Questions

Oncoplastic Breast Surgery

Practice Questions

Sentinel Lymph Node Biopsy

Practice Questions

Axillary Surgery

Practice Questions

Breast Reconstruction Techniques

Practice Questions

Male Breast Disorders

Practice Questions

Phyllodes Tumors

Practice Questions

Management of Ductal Carcinoma In Situ

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free